Insider · CIK 0001884361
Matthew Brams
Files at CING (Cingulate Inc.). First filing Feb 10, 2026, latest Feb 10, 2026.
In brief
Matthew Brams files SEC Form 4 as officer at CING (Cingulate Inc.). Since Feb 10, 2026, Matthew Brams has reported 1 open-market buy worth $9,808 and 0 open-market sells worth $0, the latest filed on Feb 10, 2026.
A track record needs three past buys with six months of prices behind them; Matthew Brams has 0, so none is measured yet.
The newest scored trade: bought $9,808 of CING on Feb 6, 2026, filed Feb 10, 2026, scored 40 (moderate). In the last 12 months: 1 buy worth $9,808 and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CING: Cingulate Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Cingulate Inc. | $9,808 1,946 shares | +72% | +131% from low0% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +53,600 | $0.00 | $0 | 53,600 | Jul 20, 2026 |
| Jul 16, 2026 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +26,400 | $0.00 | $0 | 26,400 | Jul 20, 2026 |
| Mar 9, 2026 | CING Cingulate Inc. | AGrant or award Common Stock | +4,526 | $0.00 | $0 | 9,182 | Mar 11, 2026 |
| Mar 9, 2026 | CING Cingulate Inc. | FTax withholding Common Stock | -1,025 | $0.00 | $0 | 8,157 | Mar 11, 2026 |
| Feb 6, 2026 | CING Cingulate Inc. | POpen-market purchase Common Stock | +1,946 | $5.04 | $9,808 | 4,656 | Feb 10, 2026 |
| Feb 6, 2026 | CING Cingulate Inc. | POpen-market purchase Warrant to Purchase Common Stockderivative | +1,556 | $0.10 | $156 | 1,556 | Feb 10, 2026 |
| Jul 7, 2025 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +52,500 | $0.00 | $0 | 52,500 | Jul 9, 2025 |
| Feb 18, 2025 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +17,630 | $0.00 | $0 | 17,630 | Feb 20, 2025 |
| Jan 17, 2025 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +2,748 | $0.00 | $0 | 2,748 | Jan 22, 2025 |
| Dec 31, 2024 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Jan 7, 2025 |
| Jun 11, 2024 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +63,324 | $0.00 | $0 | 63,324 | Jun 13, 2024 |
| Mar 29, 2024 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Apr 1, 2024 |
| Mar 4, 2024 | CING Cingulate Inc. | AGrant or award Stock Option (right to Buy)derivative | +16,676 | $0.00 | $0 | 16,676 | Mar 6, 2024 |
Questions about Matthew Brams
Answered from the filings on this page, as of the latest one.
Is Matthew Brams buying or selling?
In the last 12 months Matthew Brams reported 1 open-market buy worth $9,808 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $9,808 of CING on Feb 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Matthew Brams's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Brams has 0.
Where does Matthew Brams file Form 4?
Matthew Brams has filed Form 4 at CING (Cingulate Inc.) as EVP and Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.